{"nctId":"NCT01878292","briefTitle":"Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","startDateStruct":{"date":"2013-07-11","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":529,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Vilazodone 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Vilazodone"]},{"label":"vilazodone 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Vilazodone"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Vilazodone","otherNames":["Viibryd"]},{"name":"Vilazodone","otherNames":["Viibryd"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female outpatients between 12-17 years of age\n* Primary diagnosis of major depressive disorder (MDD)\n* Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater\n* Clinical Global Impressions-Severity (CGI-S) score of 4 or greater\n\nExclusion Criteria:\n\n* Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment.\n* History of suicidal behavior, or requires precaution against suicide\n* Not generally healthy medical condition\n* Seizure disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score","description":"The Children's Depression Rating Scale-Revised (CDRS-R) total score ranges from 17 (minimal or no symptoms of depression) to 133 (indicative of depression) is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 to 17 years of age and their caregivers. The CDRS-R evaluates the presence and severity of symptoms commonly associated with depression in childhood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.48","spread":"0.921"},{"groupId":"OG001","value":"-22.94","spread":"0.904"},{"groupId":"OG002","value":"-24.22","spread":"0.872"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impressions-Severity (CGI-S) Score","description":"The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated instrument used to rate the severity of the patient's current state of mental illness compared with the clinician's total experience with patients with major depressive disorder (MDD). The severity of the patient's MDD was rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating a patient who is among the most extremely ill patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"0.094"},{"groupId":"OG001","value":"-1.82","spread":"0.092"},{"groupId":"OG002","value":"-1.87","spread":"0.089"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":171},"commonTop":["Nausea","Headache","Abdominal pain upper","Diarrhoea","Vomiting"]}}}